Chris Gibson, CEO of Recursion, highlights that the merger is complementary and will industrialize drug discovery for delivering high-quality medicines at lower costs.
The merger will leverage Exscientia's precision chemistry tools and automated small molecule synthesis platform with Recursion's tech-enabled biology and chemistry exploration for enhanced capabilities.
Collection
[
|
...
]